# Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.

> **NCT04033991** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 684 (actual)

## Conditions studied

- Carcinoma
- Renal Cell

## Interventions

- **DRUG:** Sunitinib
- **DRUG:** Axitinib

## Key facts

- **NCT ID:** NCT04033991
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-27
- **Primary completion:** 2020-12-18
- **Final completion:** 2020-12-18
- **Target enrollment:** 684 (ACTUAL)
- **Last updated:** 2023-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04033991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04033991, "Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04033991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*